The Indian Institute of Medical Research (ICMR) is partnering with partners to launch and sell its new malaria vaccine, AdFalciVax. AdFalciVax is a recombinant vaccine that targets plasmodium falciparum, a common parasite in humans. The vaccine uses DNA for the whole CSP protein, potentially producing a stronger immune response. It also targets the development of p. falciparum in the mosquito’s midgut during its lifecycle, preventing infection not only in the vaccinated person but also stopping the spread of the disease by disrupting the pathogen’s lifecycle. Pre-clinical validation was conducted in collaboration with ICMR-National Institute of Medical Research and the National Institute of Immunology.
